Reviews
Head and Neck Cancer in Older Adults: Treatment Tolerance and Geriatric Assessment
Zerdan et alJournal of the National Cancer Institute

Head and neck squamous cell carcinoma (HNC) is increasingly diagnosed among older adults, a population characterized by substantial heterogeneity in physiologic reserve, comorbidity burden, functional status, and social support. Chronological age alone is an inadequate predictor of treatment tolerance and outcomes, yet it continues to influence therapeutic decision-making. Comprehensive geriatric assessment and validated assessment tools—including frailty measures and evaluations of cognitive, nutritional, and social domains—consistently provide prognostic information beyond age and conventional performance status. Emerging biomarkers of biological aging, such as immunologic aging, offer promising avenues for risk stratification but remain investigational. Additionally, older adults experience persistent underrepresentation in oncology clinical trials and disparities in access to care, alongside survivorship challenges including late toxicities, functional decline, and the need for multidisciplinary long-term rehabilitation. Addressing these gaps requires treatment adaptation and de-escalation strategies, alongside clinical trials informed by geroscience and geriatric assessment.
Key Takeaways
- Available evidence supports shifting from chronological age-based clinical decisions toward individualized head and neck cancer care guided by physiologic reserve, comprehensive geriatric assessment, and patient-centered goals.
Read the original sourceJournal of the National Cancer Institute
